Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCBY02 |
Synonyms | |
Therapy Description |
DCBY02 is a monoclonal antibody that binds to CD93 expressed on endothelial cells and blocks its interaction IGFBP7, potentially leading to increased infiltration of immune cells into the tumor microenvironment and enhanced antitumor activity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCBY02 | DCBY-02|DCBY 02 | DCBY02 is a monoclonal antibody that binds to CD93 expressed on endothelial cells and blocks its interaction IGFBP7, potentially leading to increased infiltration of immune cells into the tumor microenvironment and enhanced antitumor activity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |